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Background: Highly abundant proteins in biological fluids such as serum or cerebrospinal fluid (CSF) can hinder
the detection of proteins in lower abundance, e.g., potential biomarkers. Commercial products are available for the
depletion of albumin and immunoglobulins (Igs), although most of these kits have not been validated for dog
samples. The present study therefore examines the use of different types of depletion kits for dog CSF.
Findings: Three kits, with different mechanisms for the depletion of albumin and Igs, were tested with dog CSF
specimens. One product significantly decreased the amount of albumin; with all kits, IgG was less efficiently
removed than albumin. Mass spectrometry of the fractions eluted from the depletion columns revealed
considerable co-depletion of other CSF proteins.
Conclusions: A commercially available depletion kit was identified which depletes albumin and (to a lower extent)
immunoglobulins from dog CSF. However, the limited efficacy and the concomitant loss of other proteins from the
sample should be taken into account when using this product.
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Introduction
Biomarkers for an individual biological condition can be
of outstanding value for mapping a normal or patho-
physiological process or for studying the response to a
therapeutic intervention. Specific proteins are of particular
interest as biomarkers, as their concentrations can usually
be measured cheaply and reliably. Moreover, the enor-
mous progress in the development of proteomic tech-
niques provides highly-specific and sensitive technologies
for the identification of individual proteins, including po-
tential biomarkers [1].
Consequently, the protein profiling of body fluids is of
great interest for the identification of biomarker candi-
dates. Albumin and immunoglobulins (Igs) are the main
protein constituents of plasma or serum and other body* Correspondence: haseloff@fmp-berlin.de
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unless otherwise stated.fluids. In particular, it has been shown that albumin con-
tributes up to 60% of the protein content of cerebrospinal
fluid (CSF), which is considerably more than in plasma
[2]. However, potential biomarkers are usually proteins of
lower abundance and these are often easier to detect after
depletion of highly-abundant species. Various procedures
for depleting albumin and/or Igs have been described in
the literature (e.g., [3-9]), and diverse “depletion kits”
can be obtained from different commercial sources
which, in turn, have been tested for several parameters
(e.g., [4,10,11]).
Unfortunately, these depletion kits have been tested
for only a limited number of donor species (usually hu-
man beings and rodents). On the other hand, there is in-
creasing interest in the development of dog models for
diseases, such as the Hurler syndrome [12], the Sanfilippo
syndrome [13] or Duchenne muscular dystrophy [14].
This interest, together with the first proteomic studies di-
rected at the identification of CSF biomarkers for caninel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ity of commercial depletion kits for dog CSF.
Materials and methods
CSF samples from eight healthy adult Beagle dogs, four
male and four females, obtained by lumbar puncture, were
purchased from Seralab (Haywards Heath, UK). The pro-
vider guarantees that the specimens were collected at
USDA inspected and approved facilities. These samples
(pooled pairwise - one male, one female) were centrifuged
(2,000 × g for 10 min) to remove cells or other insoluble
substances. Proteins were precipitated overnight at 20°C
by adding four sample volumes of ice-cold acetone. The
proteins were pelleted by centrifugation (10,000 × g,
30 min, 4°C). The supernatant was removed and the pel-
let was washed with ice-cold acetone (90%). The sam-
ples were vortexed and centrifuged again (10,000 × g,
30 min, 4°C). The supernatant was discarded and the
pellets were dried at room temperature (30 min). Con-
trol experiments using dog serum were performed (see
Additional file 1) to confirm the compatibility of this
procedure, which has been recommended for proteomic
investigations using CSF [17]. The ProteoSeek™ Albu-
min/Ig Removal Kit (Thermo-Fisher, Bonn, Germany)
was applied for albumin and Ig depletion, as based on
an affinity resin column. According to the manufacturer,
this kit has been positively tested with human, monkey,
swine and rabbit samples. Depletion experiments di-
rected at albumin and Ig were also carried out using the
ProteoExtract Albumin Removal Kit (Merck Millipore,
Darmstadt, Germany, tested by the producer for human,
rabbit, rat, mouse, pig and bovine samples, with de-
creasing activity) and by the antibody-based VivapureVivapureProteoSeek














Figure 1 Polyacrylamide gel electrophoresis of Coomassie blue-staine
for removal of albumin and immunoglobulins from dog cerebrospina
complete eluate fraction (E); ProteoExtract, 3 μg (C) 5 μg (FT), complete elua
of albumin/immunoglobulin fragments; M: marker; C: dog cerebrospinal flu
procedure; E: eluate fraction(s) obtained from depletion columns.Anti-HSA/Ig Kit (Sartorius, Göttingen, Germany), de-
signed for humans, but also reactive in rat and mouse
samples (according to the product information). Pro-
teins obtained from at least three different pairwise
pooled CSF samples were applied to each kit according
to the manufacturer’s instructions after acetone precipi-
tation. Optimisation procedures suggested by the manu-
facturers (such as prolonged and/or repeated sample
application, extended mixing) did not clearly improve
the depletion results for the kits when tested in dog
serum. The protein quantities subjected to depletion
(100 μg each) were always lower than the upper limits
specified by the respective instructions, by a factor of at
least 5. Elution from the depletion columns was per-
formed as suggested by manufacturer’s protocols (if
available) or by using Laemmli buffer. Flow-through
(FT) and elution fractions (E) of CSF were reconstituted
in Laemmli buffer. Cysteine residues were reduced
using dithiothreitol (10 mM, 15 min, 60°C) and alky-
lated (55 mM iodoacetamide, 15 min, 20°C) in the dark.
All fractions (FT and E of each kit) were separated elec-
trophoretically on precast Novex Tris/Glycine 4%-20%
gels (Life Technologies, Darmstadt, Germany). Proteins
were visualised using Coomassie Brilliant Blue G-250,
and the resulting band patterns obtained from at least
three different samples were qualitatively equivalent for
the respective kit. All clearly stained bands of eluate
fractions (originating from not less than two independ-
ent samples for each kit) were excised for subsequent
mass spectrometry (MS). After in-gel digestion of pro-
teins and peptide extraction [18], MS was conducted on
a LTQ-Orbitrap XL mass spectrometer (Thermo Scien-
tific) equipped with a reverse-phase capillary liquidProteoExtract














d protein fractions obtained by applying different depletion kits
l fluid. Protein loads: ProteoSeek, 3 μg each; Vivapure, 3 μg (C, FT),
te fractions (EA/EIg); red/blue asterisks, mass spectrometric identification
id (undepleted fraction); FT: flow-through fraction after depletion
Table 1 Proteins identified by mass spectrometry with exponentially modified protein abundance index (emPAI) > 1.01
Protein Accession No.2 M.W.3 emPAImax
4
ProteoSeek Depletion Kit
Serum albumin precursor [Canis lupus familiaris] gi|55742764 69 11.85
Hemoglobin subunit beta-like [Canis lupus familiaris] gi|399567834 16 6.30
PREDICTED: Serum albumin isoform X1 [Canis lupus familiaris] gi|545520919 69 4,41
PREDICTED: Tetranectin [Canis lupus familiaris] gi|545535577 18 4.28
PREDICTED: Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 30 3.34
PREDICTED: apolipoprotein E isoform X5 [Canis lupus familiaris] gi|545488191 47 3.20
Immunoglobulin heavy chain variable region [Mus musculus] gi|81237613 13 2.90
PREDICTED: Complement component C7 isoform 1 [Canis lupus familiaris] gi|73953824 95 2.21
PREDICTED: Immunoglobulin lambda-like polypeptide 5-like isoform X1 [Canis lupus familiaris] gi|545544681 25 2.12
Prostaglandin-H2 D-isomerase precursor [Canis lupus familiaris] gi|50978842 21 2.08
Hemoglobin subunit alpha [Canis lupus familiaris] gi|44888810 15 1.96
PREDICTED: Immunoglobulin lambda-like polypeptide 5-like isoform X2 [Canis lupus familiaris] gi|545544683 25 1.77
PREDICTED: Gelsolin [Canis lupus familiaris] gi|545518174 94 1.70
PREDICTED: Fibulin-1 isoform X1 [Canis lupus familiaris] gi|545514459 78 1.63
Immunoglobulin gamma heavy chain A [Canis lupus familiaris] gi|17066524 52 1.63
Immunoglobulin gamma heavy chain B [Canis lupus familiaris] gi|17066526 52 1.61
PREDICTED: EGF containing fibulin-like extracellular matrix protein 1 isoform X3 [Canis lupus familiaris] gi|57092953 55 1.60
PREDICTED: Angiotensinogen [Canis lupus familiaris] gi|545494757 52 1.53
Immunoglobulin heavy chain constant region CH2 [Canis lupus familiaris] gi|124390009 12 1.45
Ig heavy chain V region GOM [Canis lupus familiaris] gi|123768 12 1.37
Immunoglobulin heavy chain constant region CH4 [Canis lupus familiaris] gi|124390013 14 1.21
PREDICTED: LOW QUALITY PROTEIN: Serotransferrin isoform 1 [Canis lupus familiaris] gi|545539001 85 1.16
Protease serine 4 isoform B [Homo sapiens] gi|33126535 28 1.13
Clusterin precursor [Canis lupus familiaris] gi|50979240 52 1.08
PREDICTED: Plasminogen isoform X1 [Canis lupus familiaris] gi|545485785 91 1.06
Vivapure Depletion Kit
Serum albumin precursor [Canis lupus familiaris] gi|55742764 69 11.30
Hemoglobin subunit beta-like [Canis lupus familiaris] gi|399567834 16 5.69
PREDICTED: Apolipoprotein A-I [Canis lupus familiaris] gi|73955106 30 4.80
PREDICTED: Angiotensinogen [Canis lupus familiaris] gi|545494757 52 3.35
PREDICTED: Serum albumin isoform X1 [Canis lupus familiaris] gi|545520919 69 2.98
Hemoglobin subunit alpha [Canis lupus familiaris] gi|44888810 15 2.91
Immunoglobulin gamma heavy chain B [Canis lupus familiaris] gi|17066526 52 2.58
PREDICTED: Immunoglobulin lambda-like polypeptide 5-like isoform X1 [Canis lupus familiaris] gi|545544681 25 1.62
PREDICTED: Immunoglobulin lambda-like polypeptide 5-like isoform X2 [Canis lupus familiaris] gi|545544683 25 1.62
Prostaglandin-H2 D-isomerase precursor [Canis lupus familiaris] gi|50978842 21 1.33
Albumin, isoform CRA_h [Homo sapiens] gi|119626071 69 1.21
Immunoglobulin heavy chain constant region CH2 [Canis lupus familiaris] gi|124390009 12 1.18
Immunoglobulin gamma heavy chain A [Canis lupus familiaris] gi|17066524 52 1.16
beta-2-Glycoprotein 1 precursor [Canis lupus familiaris] gi|54792721 38 1.00
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Table 1 Proteins identified by mass spectrometry with exponentially modified protein abundance index (emPAI) > 1.01
(Continued)
ProteoExtract Depletion Kit
Immunoglobulin heavy chain variable region [Mus musculus] gi|81237613 13 2.39
Hemoglobin subunit alpha [Canis lupus familiaris] gi|122508 15 1.64
1The complete list of identified proteins is available at Additional file 2.
2Accession number in NCBI database.
3M.W., Protein molecular weight in kDa.
4The emPAI value expresses mass spectrometry-based quantitation of protein abundance and is calculated according to emPAI ¼ 10
Nobserved
Nobservable−1, (Nobserved, Nobservable,
number of observed/observable peptides); cf. http://www.matrixscience.com/help/quant_empai_help.html for more details.
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Semrau GmbH, Sprockhövel, Germany). The generated
peak lists and the MASCOT server (version 2.2, Matrix
Science Ltd., London/UK) were used to search against the
non-redundant NCBI database (version 131022) restricted
to mammals (1,974,848 sequences). A maximum of two
missed cleavages was allowed, and the mass tolerance of
precursor and sequence ions was set to 10 ppm and
0.35 Da, respectively. The program Scaffold (version 4.2.1,
Proteome Software Inc., Portland OR, USA) was used to
validate MS/MS-based peptide and protein identifications,
which were accepted if established at greater than 99.0%
probability with at least two identified peptides.
Results and discussion
Different depletion kits for albumin and Igs were tested
using dog CSF samples. Numerous other products for
depletion are commercially available [19]. However, data
providing an assessment of depletion kits is sparse even
for human CSF, and several authors have found that these
depletion kits give relatively low reproducibility. Previous
work has shown that more than 95% albumin was de-
pleted from human CSF with the ProteoSeek kit, resulting
in a 20% increase in the number of detected proteins
(from 135 to 163) [20]. The Vivapure anti-HSA/IgG kit
was applied to human CSF and depleted albumin less
effectively than the Sigma anti-HSA/IgG column or the
ProteaPrep HSA/IgG column [21]. The Vivapure kit was
found to be superior to the ProteoExtract kit for the ana-
lysis of the recovery of the prostate-specific antigen in hu-
man serum samples [22]. On the other hand, in studies on
human serum, ProteoExtract has been found to give satis-
factory reproducibility and specificity [23]. Other authors
(e.g., [24]) used the ProteoExtract kit for depleting human
CSF, without reporting problems.
The Coomassie-stained gels shown in Figure 1 demon-
strate that none of the kits gave satisfactory depletion of
albumin and Igs from dog CSF samples. The ProteoSeek
kit clearly exhibited the highest efficacy with respect to
albumin; the amounts depleted from CSF by Vivapure
and ProteoExtract kits were lower or negligible, respect-
ively. Proteins identified in bands of the eluate gel lanes
are given in Table 1 which lists proteins with substantialabundance, i.e., exponentially modified protein abun-
dance index (emPAI) > 1.0. For approximately 56% of the
canine proteins found, at least one isoform coincides
with the human CSF proteome previously reported [25].
Albumin was enriched in the eluate fractions obtained
from the ProteoSeek and Vivapure kits, but only one
low abundant fragment was found in the eluate from the
ProteoExtract kit (see Additional file 2 showing all
eluted proteins identified by mass spectrometry). In
agreement with the protein staining, immunoglobulin
fragments were detected with lower emPAI values in the
eluate fractions obtained by application of the depletion
kits. However, additional proteins were identified by MS
in all these fractions. Significant quantities of haemoglo-
bin (obviously a contamination of the CSF samples) were
found in the eluate fractions of all kits tested. As ex-
pected from the gel staining, the greatest co-depletion
was observed for the ProteoSeek kit (115 proteins de-
tected in total), but numerous non-targeted proteins
have been also identified in samples obtained with the
Vivapure kit (total proteins, 64), whereas only 3 detect-
able proteins were eluted from the columns of the Pro-
teoExtract kit (see Additional file 2. Table showing all
eluted proteins identified by mass spectrometry).
Unspecific binding, either to the matrix or to the bait
material, is a well-known phenomenon occurring in
affinity purification approaches. In addition, one has to
expect that proteins bound to albumin will recover in
the eluate fractions. All of the proteins identified in the
eluate were also present in the recently characterised CSF
“albuminome” [21] for ProteoExtract, compared to 44% for
Vivapure and 30% for ProteoSeek, although this comparison
does not consider different experimental conditions and
species. Since albuminome data were obtained in human
CSF samples, it is likely that the co-depletion observed in
our experiments results from both albumin binding and
unspecific association.
In conclusion, our results do not support the use of
these kits for depletion of albumin and Igs from dog CSF
samples. Even with the most active kit tested, albumin and
Igs were only incompletely removed. This was accompan-
ied by co-depletion of numerous other proteins, a particu-
lar drawback for the identification of potential biomarkers.
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Additional file 1: Gel electrophoresis of dog serum before and after
albumin depletion using the ProteoSeek kit. The flow-through
fraction and the column eluate were compared with and without prior
acetone precipitation.
Additional file 2: Table showing all eluted proteins identified by
mass spectrometry.
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